Industry News

Moderna will break ground in mid-2023 on a £150 million complex for the creation of mRNA vaccines and therapeutics in the United Kingdom. Located on the Harwell Campus in Oxfordshire, the Moderna Innovation and Technology Centre (MITC) will comprise two 145,000-sf buildings. The Drug Substance Manufacturing Unit will leverage next-generation automation systems to produce high volumes of vaccine materials, accompanied by an early-stage R&D hub that will support clinical trials.

The Hurley Group has transformed an existing office building in New Haven to create the Elm City Bioscience Center. Designed by Svigals + Partners, the adaptive reuse project offers over 100,000 sf of leasable research space for startup companies.

Mispro Biotech Services is building a 10,000-sf contract vivarium in Boston's Seaport District. The state-of-the-art facility will enable life science companies of all sizes to conduct preclinical drug development studies on rodents with the support of Mispro’s husbandry services, technical expertise, and regulatory compliance oversight.

The United States Congress passed Senate Bill 5002 in late 2022 to allow methods other than animal testing to be employed to establish drug efficacy and safety. Dubbed the FDA Modernization Act 2.0, the legislation supports the inclusion of cell-based assays, computer models, and microphysiological systems such as organ chips in preclinical testing operations. The bill also rescinds a stipulation that animal studies must be used when seeking a license for a biological product that is biosimilar or interchangeable with another product.

Pfizer is expanding its Chesterfield campus with the construction of a $60 million addition to support vaccine research and development. Providing leading-edge labs, offices, and support spaces, the three-story, 37,000-sf project will adjoin an existing 261,000-sf facility that opened in 2019. A two-story bridge with a covered plaza will link the completed structure to the rest of the 31-acre site.